|
|
|
|
|
|
Sponsored by: |
Eisai Medical Research Inc. |
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00069277 |
The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and potentially other, tumor types.
Condition | Intervention | Phase |
Cancer |
Drug: E7389 |
Phase I |
MedlinePlus related topics: | Cancer |
Drug Information available for: | E7389 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors |
Enrollment: | 35 |
Study Start Date: | August 2003 |
Study Completion Date: | April 2005 |
Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |||||
Premiere Oncology | |||||
Santa Monica, California, United States, 90404 | |||||
Cancer Institute Medical Group | |||||
Los Angeles, California, United States, 90025 | |||||
United States, New Jersey | |||||
New Brunswick, New Jersey, United States, 08901 |
Eisai Medical Research Inc. |
Study Director: | Dale Schuster, Ph.D | Eisai Medical Research Inc. |
Responsible Party: | Eisai Medical Research ( Dale Shuster, Ph.D ) |
Study ID Numbers: | E7389-A001-102 |
First Received: | September 19, 2003 |
Last Updated: | February 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00069277 |
Health Authority: | United States: Food and Drug Administration |
|
|